TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01515137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Study: NCT03962738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00554359
Drug: I5NP (a small interfering RNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV injection of experimental drug
Study: NCT00554359
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV injection of saline
Study: NCT03857893
Drug: pH-Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
Study: NCT01423526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, oral administration, single administrations
Study: NCT04074174
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
Study: NCT02355431
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
Study: NCT00924326
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
Study: NCT00924326
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
Study: NCT00509067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
Study: NCT01155986
Drug: Placebo topical plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrogel plaster
Study: NCT03749369
Drug: Salvadora Persica Root
Normalized name: SALVADORA PERSICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvadora Persica Gel
Study: NCT02577614
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo after cardiopulmonary bypass
Study: NCT00175617
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
Study: NCT03912337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once every 4 weeks. SC injection.
Study: NCT02871778
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02871778
Drug: Placebo (0.17% saline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02134080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally at 4mg daily for four weeks.
Study: NCT02261779
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01638078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, pill, once p.d., 6 weeks
Study: NCT04183283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01466530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
Study: NCT01386294
Drug: Universal placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
Study: NCT01543828
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: delivered via single-dose dry-powder inhaler
Study: NCT02226952
Drug: BILN 2061 W, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02226952
Drug: BILN 2061 W, medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00073528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (which matched with lapatinib tablet)
Study: NCT02226952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01148095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04625114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).
Study: NCT04625114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
Study: NCT00003702
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intramuscularly
Study: NCT00535275
Drug: Chemotherapy with platine
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
Study: NCT01318499
Drug: Nepafenac Ophthalmic Suspension, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
Study: NCT00602095
Drug: dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg vaginal gel every 6 hours until progress
Study: NCT00843518
Drug: LY451395
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
Study: NCT00843518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice daily for 12 weeks
Study: NCT00962442
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosé 5% perfusion for 14 days, intravenously
Study: NCT02985099
Drug: SRP plus placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP followed by placebo gel placement into intrabony defect
Study: NCT01059110
Drug: 5-Fluoro-Uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cream, one application every night, during 12 hours, for 90 days
Study: NCT03770091
Drug: Theraworx
Normalized name: Theraworx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theraworx foam applied to skin and/or compression wrap
Study: NCT03770091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo foam
Study: NCT03951051
Drug: Olmetec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
Study: NCT00458796
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00995475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01079988
Drug: Retinoids
Normalized name: Retinoids for cancer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
Study: NCT01079988
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
Study: NCT01079988
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
Study: NCT01079988
Drug: Systemic corticosteroids/methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
Study: NCT03252353
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT02431897
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
Study: NCT03044249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT02782520
Drug: Hypertonic saline (3ml/kg) fluid expansion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00279019
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
Study: NCT00279019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
Study: NCT00391105
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00887263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg TID
Study: NCT00857623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, once daily
Study: NCT04035603
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
Study: NCT02721888
Drug: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227602
Drug: Mango polyphenolics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen mango pack will be provided (200\~400g per day).
Study: NCT03639311
Drug: RPV LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered RPV LA (900 mg), Q2M, as intramuscular injection.
Study: NCT03843281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: s. above
Study: NCT02767310
Drug: Rosuvastatin 20 mg film-coated tablets
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 20 mg
Study: NCT02511353
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ivermectin.
Study: NCT01721876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Volasertib
Study: NCT02767310
Drug: Crestor 20 mg film-coated tablets
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 20 mg
Study: NCT00360906
Drug: Triomar™ (omega-3 fatty acids)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03877536
Drug: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Normalized name: Genvoya 150mg-150mg-200mg-10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 tablet per day throughout study duration (96 weeks).
Study: NCT03068260
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g orally administered postoperatively
Study: NCT02760979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum one year after surgery
Study: NCT00687440
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.
Study: NCT01979536
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01979536
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01979536
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT03068260
Drug: Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered postoperatively
Study: NCT00528021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Only
Study: NCT04395677
Drug: AB-106
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD
Study: NCT02349399
Drug: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
Study: NCT00382720
Drug: Docetaxel + Oxaliplatin + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.
Study: NCT00682448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo. Subjects will remain on placebo for 6 months.
Study: NCT01740960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
Study: NCT00191295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00119379
Drug: NucleomaxX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NucleomaxX 36 grams TID every other day
Study: NCT00970697
Drug: Duoderm Hydrogel™
Approvals — FDA: no, EMA: no, PMDA: no
Description: The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
Study: NCT02414399
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration of Azithromycin
Study: NCT02414399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of taste/appearance/bottle-matched inactive substance
Study: NCT00709553
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 10 mg od
Study: NCT04641299
Drug: AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study: NCT04641299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT00322465
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg orally, twice daily for 7 days.
Study: NCT00322465
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
Study: NCT00411203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03377842
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
Study: NCT03377842
Drug: apatinib and FOLFOX regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
Study: NCT03029715
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narcotics
Study: NCT04473170
Drug: COVID-19 standard care
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAE National Guidelines for Clinical Management and Treatment of COVID-19.
Study: NCT03846570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (identically package) administered BID
Study: NCT05500820
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A repeat oral dose of matching placebo once daily for 10 days.
Study: NCT02183415
Drug: BI 1356 BS, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01814020
Drug: MOB015B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00699803
Drug: T-PRED
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-PRED sterile ophthalmic solution
Study: NCT02183415
Drug: BI 1356 BS, medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03486990
Drug: TIMP-GLIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion.
Study: NCT00044226
Drug: ML-04A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02809131
Drug: cephalexin, or levofloxacin, or clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post operative oral antibiotics
Study: NCT02177396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01612468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/day subcutaneous
Study: NCT00187096
Drug: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for additional details of treatment interventions.
Study: NCT01767298
Drug: Valsartan/Hydrochlorothiazide
Normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration or fixed dose combination
Study: NCT02464709
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
Study: NCT04059783
Drug: STW5 (Iberogast®, BAY98-7411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
Study: NCT01081678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous (under the skin) injection
Study: NCT03755895
Drug: Kalinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will have brachytherapy detachment under Kalinox
Study: NCT03965858
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DPI is to be administered via dry powder inhaler.
Study: NCT00657865
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02819635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet for oral administration
Study: NCT04511832
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
Study: NCT02057796
Drug: ART (Atripla, Truvada, Efavirenz, Combivir)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2
Study: NCT00359021
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily until commercially available
Study: NCT03719612
Drug: DEFINITY®
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single dose of DEFINITY®
Study: NCT03619005
Drug: Placebo Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of a placebo vaginal insert.
Study: NCT03619005
Drug: Prasterone 6.5 mg (0.50%) Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Study: NCT00865696
Drug: REMERON® 15 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
Study: NCT02629094
Drug: Inspra /Eplerenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.